Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106975 | 0.79 | KMT2A (0.62) | POLBLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL353706 | 0.76 | — | — | |
| SCHEMBL9200428 | 0.76 | KMT2A (0.59) | POLBLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24882693 | 0.75 | KMT2A (0.55) | POLBLMNAKMT2ASMN1; SMN2HSPA8 | |
| SCHEMBL1300418 | 0.75 | ALDH1A1 (0.56) | POLBLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10507692 | 0.75 | CES2 (0.61) | POLBLMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18906021 | 0.74 | KMT2A (0.61) | POLBLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15743809 | 0.74 | KMT2A (0.57) | POLBLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7375736 | 0.74 | KMT2A (0.54) | POLBLMNAKMT2ASMN1; SMN2HSPA8 | |
| SCHEMBL7375739 | 0.74 | KMT2A (0.57) | POLBLMNAKMT2ASMN1; SMN2HSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275625-A1 | Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110269668-A1 | Fused Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269668-A1 | Fused Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | MMP13, MMP2, MMP3 | POLB 959/4885LMNA 1436/4885KMT2A 3514/4885 |
| US-20110275625-A1 | Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | MMP13, MMP3, MMP11 | POLB 977/4885LMNA 1468/4885KMT2A 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.